Trial Profile
A 30-days treatment effects of MK-7123 on humoral immunity and delayed-type hypersensitivity in healthy volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Dec 2015
Price :
$35
*
At a glance
- Drugs Navarixin (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacodynamics
- 05 Dec 2015 New trial record